Immunoconjugates targeting syndecan-1 expressing cells and use thereof
AssigneesBiotest AG, ImmunoGen, Inc.
InventorViktor Goldmakher
Life of this patent
Estimating the term…
Abstract
Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1.
Claims25
A method for inhibiting, delaying and/or preventing the growth of a tumor comprising syndecan-1 expressing tumor cells and/or spread of syndecan-1 expressing tumor cells in a patient in need thereof, comprising
- administering to said patient at least one immunoconjugate in a growth of said tumor and/or spreading of said tumor cells inhibiting or reducing amount,
- wherein said immunoconjugate comprises at least one effector molecule and at least one targeting agent, and
- wherein said immunoconjugate selectively inhibits, delays or prevents the growth and/or spread of syndecan-1 expressing cells.
A method for inhibiting, delaying and/or preventing the growth of a tumor and/or spread of malignant tumor cells in a patient in need thereof, comprising
- (a) administering to said patient one or more cancer drugs and/or radiation in an amount effective to reduce tumor load;
- and
- (b) administering to said patient at least one immunoconjugate in a growth of a tumor and/or spreading of tumor cells inhibiting, delaying or preventing amount, wherein said immunoconjugate selectively inhibits, delays or prevents the growth and/or spread of syndecan-1 expressing cells.
A method for treating a subject having a condition that would benefit from the selective suppression of myeloma cell survival, the method comprising:
- (a) providing at least one immunoconjugate that selectively binds to syndecan-1 expressed on myeloma cells;
- and
- (b) administering the immunoconjugate to the subject to selectively decrease survival or growth of said myeloma cells of said subject.
A method for treating inhibiting, delaying and/or preventing the growth of tumor cells in a cell culture containing syndecan-1 expressing tumor cells and non-tumor cells comprising
- administering a growth of syndecan-1 expressing tumor cells inhibiting, delaying and/or preventing effective amount of the immunoconjugate comprising:
- at least one targeting agent selectively targeting cell-surface expressed syndecan-1,
- at least one effector molecule,
- wherein said effector molecule has, in its native form, high non-selective cytotoxicity,
- wherein said targeting agent is functionally attached to said effector molecule to form said immunoconjugate, and
- wherein said effector molecule has substantially no non-selective cytotoxicity when part of said immunoconjugate.
Dependencies are inferred from the claim text.